Urinary Bladder Neoplasms

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 2204

Special Issue Editors


E-Mail Website
Guest Editor
Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wrocław Medical University, 50-367 Wrocław, Poland
Interests: bladder cancer; urothelial cancer; endoscopy; UTUC
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Public Health, Wroclaw Medical University, 50-367 Wrocław, Poland
Interests: statistical analysis; data management

Special Issue Information

Dear Colleagues,

Bladder cancer is one of the most common malignancies. Each year, more than 300,000 patients are diagnosed with this cancer worldwide. The incidence is higher in the male population, and in many countries bladder cancer is one of the top five most common malignant neoplasms in men. Furthermore, bladder cancer is a deadly disease, causing more than 160,000 deaths worldwide each year. Globally, the cancer age-standardized mortality rate (per 100,000 person/years) is 3.3 for men vs. 0.86 for women.

In this Special Issue of Life, we present a series of high-quality original articles and meta-analyses concerning bladder cancer, illustrating the current developments in both diagnosis and treatment.

Dr. Wojciech Krajewski
Dr. Andrzej Tukiendorf
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • urothelial cancer
  • NMIBC
  • MIBC

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 513 KiB  
Article
Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors
by Alexander Marquardt, Mario Richterstetter, Helge Taubert, Arndt Hartmann, Bernd Wullich, Verena Lieb, Laura Bellut, Sven Wach and Hendrik Apel
Life 2022, 12(5), 641; https://doi.org/10.3390/life12050641 - 26 Apr 2022
Viewed by 1641
Abstract
One pillar in treating non-muscle-invasive bladder cancer (NMIBC) is the complete and high-quality transurethral resection of the primary tumor (TURBT). However, even after a high-quality primary resection, the residual tumor risk is considerable, thus requiring a re-TURBT. Resections performed with the aid of [...] Read more.
One pillar in treating non-muscle-invasive bladder cancer (NMIBC) is the complete and high-quality transurethral resection of the primary tumor (TURBT). However, even after a high-quality primary resection, the residual tumor risk is considerable, thus requiring a re-TURBT. Resections performed with the aid of a photodynamic diagnostics report improved recurrence-free survival rates and increased detection rates of carcinoma in situ (CIS). This monocentric retrospective study reports on patients treated with an extended TURBT procedure using conventional white-light cystoscopy or photodynamic diagnostics (PDD). Only patients undergoing a TURBT resection for their primary tumor were included in the statistical analysis. Recurrence-free survival and overall survival were the clinical endpoints. Mann–Whitney U tests and chi-squared tests were used for descriptive intergroup comparisons. The associations with overall survival and recurrence-free survival were determined by univariate and multivariate analyses. The test results were considered significant when p was < 0.05. In comparison to conventional white-light cystoscopy, PDD increased the detection rates of CIS (p = 0.004) and tumor multifocality (p = 0.005) and led to reduced residual tumor incidence at the primary resection site (p < 0.001). Likewise, tumor recurrence rates were reduced in the PDD cohort (p < 0.001). Patient age and the presence of residual tumor at the primary resection site were identified as independent predictors of overall survival. For recurrence-free survival, only the PDD resection method was an independent predictor (HR = 0.43; p < 0.001). In summary, we demonstrated that the utilization of PDD techniques was associated with improved detection rates of CIS and multifocal tumors and with reduced recurrence rates. The extended resection protocol allowed us to determine that PDD resections lead to a reduced residual tumor rate at the initial resection site. This residual tumor state at the resection site, determined by extended TURBT, became an independent predictor of long-term survival. On the other hand, the PDD technique was confirmed as the only independent predictor of recurrence-free survival. Full article
(This article belongs to the Special Issue Urinary Bladder Neoplasms)
Show Figures

Figure 1

Back to TopTop